** Drug developer Alpha Cognition ACOG.O rises 12.5% to $5.91
** ACOG says it has launched its oral therapy, Zunveyl, commercially to treat mild to moderate Alzheimer's disease (AD)
** Alzheimer's is a progressive brain disorder that slowly destroys memory, thinking skills, and eventually the ability to do simple tasks, which is the most common form of dementia affecting nearly 7 million people
** Co says patients can now access the drug in 5 milligram (mg), 10 mg and 15 mg doses
** Zunveyl was approved by the FDA to treat AD in July 2024
** Brokerage H.C. Wainwright estimates Zunveyl to generate $540 millon in peak annual sales in the US by the late 2030s
** As of last close, ACOG down ~65% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.